Fexapotide clinical trials
Also written NX-1207.
How each study uses fexapotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NX-1207
- 5
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Nymox Corporation (6) · RECORDATI GROUP (1)
Studies
Open first, then newest update. How each study uses fexapotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPHTerminatedPhase 3RECORDATI GROUPNCT02003742Written as NX-1207
- Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018CompletedPhase 3Nymox CorporationNCT00945490Written as NX-1207
- Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate CancerCompletedPhase 2Nymox CorporationNCT01620515Written as NX-1207 2.5 mg
- Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)CompletedPhase 3Nymox CorporationNCT01846793Written as NX-1207
- Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)CompletedPhase 3Nymox CorporationNCT01438775Written as NX-1207
- Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)CompletedPhase 3Nymox CorporationNCT00918983Written as NX-1207
- Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)CompletedPhase 2Nymox CorporationNCT00759135Written as 2.5 mg NX-1207
Codes
What other systems call fexapotide · ClinicalTrials.gg INT001197
- MeSH (NLM) C000654327fexapotideOne source NLM
- UNII (FDA) 9L8TV1O7E0FEXAPOTIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27272699fexapotideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174582FexapotideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654327 | fexapotide | One source NLM |
| UNII (FDA) | 9L8TV1O7E0 | FEXAPOTIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27272699 | fexapotide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174582 | Fexapotide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.